The Business of Biofabrication

The Advanced Research Projects Agency for Health (ARPA-H) has recently funded several large initiatives under its Personalized Regenerative Immunocompetent Nanotechnology Tissue (PRINT) program aimed at advancing implantable bioengineered organs. Among them is a $25.8 million project led by Shaochen Chen at University of California San Diego that seeks to develop a patient-specific, 3D bioprinted human liver.

While other PRINT-funded projects focus on engineered grafts or partial tissue replacements, the UC San Diego effort is notable for its explicit goal of fabricating a full, transplantable organ derived from a patient’s own cells. The project brings together researchers in engineering, liver biology, imaging, surgery, and artificial intelligence with the aim of creating “made-to-order” livers that could eventually replace donor organs.

A Technology Platform Built Over Two Decades

The project builds on more than twenty years of bioprinting research in Chen’s laboratory. Unlike extrusion-based systems used by many bioprinting platforms, Chen’s method uses digitally controlled light patterns to solidify cell-laden biomaterials layer by layer.

This technique allows tissues to be fabricated rapidly while maintaining micron-scale structural resolution, enabling the recreation of complex biological architectures such as vascular networks. The approach has previously been used to generate small liver tissue models derived from induced pluripotent stem cells, which replicated aspects of liver structure and function in vitro.

A notable aspect of the program is that the printing technology has already undergone partial commercial translation. Earlier versions of Chen’s laboratory platform were spun out into the startup Allegro 3D, which later became part of the bioprinting company Cellink. The ARPA-H project therefore begins from a technology base that has already moved beyond a purely academic prototype.

AI-Assisted Vascular Design

A major technical challenge in organ bioprinting is the creation of vascular systems capable of sustaining large tissues. Without adequate blood supply, printed organs cannot maintain viability after implantation.

To address this issue, the UC San Diego team has incorporated artificial intelligence into the organ design process, using computational models to generate vascular networks capable of supporting large tissue volumes. These designs are then translated into printable architectures using the lab’s high-resolution photopolymerization platform.

The combination of AI-assisted design and high-speed light-based printing represents a key technical direction for the project.

Industry and Manufacturing Partners

The program also incorporates an industry collaboration with Allele Biotechnology, a San Diego company specializing in personalized stem cell technologies and cell manufacturing.

Allele’s facilities are designed to produce cell populations under regulatory-compliant conditions, which could support the transition of printed tissues from laboratory demonstrations to clinical-grade manufacturing. This partnership reflects a broader recognition in the regenerative medicine sector that cell production infrastructure is a critical component of organ biofabrication.

What Differentiates the UC San Diego Project

Taken together with other PRINT-funded efforts, the UC San Diego project illustrates several distinct characteristics:

Whole-organ objective
While some PRINT initiatives focus on tissue patches or organ-support systems, this program explicitly targets a full-scale transplantable liver.

Patient-specific cell sourcing
The strategy relies on induced pluripotent stem cells derived from the patient, which could reduce immune rejection and the need for long-term immunosuppressive drugs.

Light-based high-resolution printing
The platform differs from many bioprinting approaches by using digital light processing rather than extrusion, enabling rapid fabrication of detailed tissue architectures.

Integration of AI into organ design
The project incorporates computational tools to design vascular systems capable of sustaining larger biological constructs.

Position Within the PRINT Portfolio

Across the PRINT program, ARPA-H appears to be supporting multiple technological pathways toward implantable organs, including engineered grafts, biofabricated tissues, and hybrid biological devices.

The UC San Diego effort represents one of the most organ-centric approaches in this portfolio. Rather than augmenting existing organs or replacing partial functions, the project focuses on the longer-term objective of manufacturing a complete transplantable liver.

Whether such systems can reach clinical deployment remains uncertain. However, programs like PRINT suggest that federal agencies are increasingly willing to fund large multidisciplinary efforts aimed at advancing organ-scale biofabrication technologies.

If successful, the work could contribute to addressing the persistent shortage of donor organs and reshape the long-term trajectory of transplantation medicine.

For more info visit original article here.